Related Experiment Video
Updated: May 6, 2026

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
Abnormal gephyrin immunoreactivity associated with Alzheimer disease pathologic changes
Chadwick M Hales1, Howard Rees, Nicholas T Seyfried
1From the Department of Neurology (CMH, HR, AIL, JJL, TSW), Center for Neurodegenerative Disease (CMH, HR, NTS, EBD, DMD, MG, AIL, JJL, TSW), Departments of Biochemistry (NTS) and Human Genetics (EBD, TSW), and Pathology and Laboratory Medicine (MG), Emory University School of Medicine, Atlanta, Georgia; Department of Pathology, University of Washington, Seattle, Washington (TJM); Departments of Pathology and Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland (JCT); National Institute of Aging, National Institutes of Health, Bethesda, Maryland (MT); and Atlanta Veterans Administration Medical Center, Atlanta, Georgia (TSW).
Abstract:
Many neurodegenerative disorders involve the abnormal accumulation of proteins. In addition to the pathologic hallmarks of neurofibrillary tangles and β-amyloid plaques in Alzheimer disease (AD), here we show that abnormal accumulations of gephyrin, an inhibitory receptor-anchoring protein, are highly correlated with the neuropathologic diagnosis of AD in 17 AD versus 14 control cases. Furthermore, gephyrin accumulations were specific for AD and not seen in normal controls or other neurodegenerative diseases including Parkinson disease, corticobasal degeneration, and frontotemporal degeneration. Gephyrin accumulations in AD overlapped with β-amyloid plaques and, more rarely, neurofibrillary tangles. Biochemical and proteomic studies of AD and control brain samples suggested alterations in gephyrin solubility and reveal elevated levels of gephyrin lower-molecular-weight species in the AD insoluble fraction. Because gephyrin is involved in synaptic organization and synaptic dysfunction is an early event in AD, these findings point to its possible role in the pathogenesis of AD.
More Related Videos
06:02Experimental Approaches for Biochemical Analysis of Glial Fibrillary Acidic Protein and Its Disease-associated Variants
Published on: November 28, 2025
06:43A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes
Published on: February 5, 2018
Related Concept Videos
Alzheimer Disease ll: Pathophysiology
Alzheimer Disease l: Introduction
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...